Julie Rubinstein

Person

Last mentioned: Mar 14, 2026

Timeline

Mar 14, 2026
Insider Sales Reported

SEC filings confirm share liquidations by COO Julie Rubinstein and SVP Susan Bobulsky.
Feb 15, 2026
Q4 2025 Earnings

Adaptive reports continued growth in clonoSEQ test volume and revenue.
Nov 10, 2025
Clinical Expansion

Company announces new data supporting T-cell mapping in autoimmune research.

Stories mentioning Julie Rubinstein 1

Adaptive Biotechnologies Insiders Sell Over 60,000 Shares Amid Market Shift

Adaptive Biotechnologies (NASDAQ: ADPT) executives Julie Rubinstein and Susan Bobulsky have sold a combined 60,398 shares, signaling a notable period of insider liquidation. The transactions occur as the company continues to navigate the competitive landscape of immune-driven diagnostics and MRD monitoring.

Mar 14, 2026 2 sources